A systems biology approach to define SARS-CoV-2 correlates of protection.
Brady C. et al, (2025), NPJ vaccines, 10
Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies.
Laczi D. et al, (2025), European journal of medicinal chemistry, 291
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.
Laidlaw SM. et al, (2025), Microbiology spectrum
Using minor variant genomes and machine learning to study the genome biology of SARS-CoV-2 over time.
Dong X. et al, (2025), Nucleic acids research, 53
Host-pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses.
Hood G. and Carroll M., (2024), Current opinion in virology
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Performance of an envelope glycoprotein-based multiplex immunoassay for Ebola virus antibody detection in a cohort of Ebola virus disease survivors.
Roe MD. et al, (2024), Journal of virological methods, 331
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim YJ. et al, (2024), British journal of haematology, 205, 440 - 451
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS. et al, (2024), The Lancet. Rheumatology, 6, e339 - e351
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Cornish K. et al, (2024), Open biology, 14
Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.
Akoi Boré J. et al, (2024), Nature communications, 15
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Ali M. et al, (2024), Clinical and Experimental Immunology
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Mellors J. and Carroll M., (2024), Cellular and molecular life sciences : CMLS, 81
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
Murray SM. et al, (2024), Journal of Hepatology, 80, 109 - 123
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Ratcliffe H. et al, (2023), iScience, 26, 108500 - 108500
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Wilkinson T. et al, (2023), ERJ Open Research, 9, 00249 - 2023